Use of 11C-PE2I PET in Differential Diagnosis of Parkinsonian Disorders

被引:35
作者
Appel, Lieuwe [1 ,2 ]
Jonasson, My [2 ,4 ]
Danfors, Torsten [1 ,2 ]
Nyholm, Dag [3 ]
Askmark, Hakan [3 ]
Lubberink, Mark [2 ,4 ]
Soerensen, Jens [1 ,2 ]
机构
[1] Univ Uppsala Hosp, PET Ctr, Dept Med Imaging, S-75185 Uppsala, Sweden
[2] Uppsala Univ, Dept Radiol Oncol & Radiat Sci, Sect Nucl Med & PET, Uppsala, Sweden
[3] Uppsala Univ, Dept Neurosci Neurol, Uppsala, Sweden
[4] Univ Uppsala Hosp, S-75185 Uppsala, Sweden
基金
瑞典研究理事会;
关键词
parkinsonism; dopamine transporter; DAT; overall brain functional activity; PET; SPECT; DOPAMINE TRANSPORTER BINDING; PROGRESSIVE SUPRANUCLEAR PALSY; SPECT; SYSTEM; SEROTONIN; QUANTIFICATION; I-123-FP-CIT; MANAGEMENT; ACCURACY; CRITERIA;
D O I
10.2967/jnumed.114.148619
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In idiopathic Parkinson disease and atypical parkinsonian disorders, central dopaminergic and overall brain functional activity are altered to different degrees, causing difficulties in achieving an unambiguous clinical diagnosis. A dual examination using I-123-FP-CIT (I-123-N-omega-fluoropropyl- 2 beta-carbomethoxy-3 beta-(4-iodophenyl) nortropane, or I-123-ioflupane) SPECT and F-18-FDG PET provides complementary information on dopamine transporter (DAT) availability and overall brain functional activity, respectively. Parametric images based on a single, dynamic C-11-PE2I (N-(3-iodoprop-2E-enyl)-2 beta-carbomethoxy-3 beta-(4-methyl-phenyl) nortropane) scan potentially supply both DAT availability (nondisplaceable binding potential [BPND]) and relative cerebral blood flow (relative delivery [R-1]) at voxel level. This study aimed to evaluate the validity of C-11-PE2I PET against the dual-modality approach using I-123-FP-CIT SPECT and F-18-FDG PET. Methods: Sixteen patients with parkinsonian disorders had a dual examination with F-18-FDG PET and I-123-FP-CIT SPECT following clinical routines and additionally an experimental C-11-PE2I PET scan. Parametric BPND and R-1 images were generated using receptor parametric mapping with the cerebellum as a reference. T1-weighted MR imaging was used for automated definition of volumes of interest (VOI). The DAT VOIs included the basal ganglia, whereas the overall brain functional activity was examined using VOIs across the brain. BPND and R-1 values were compared with normalized I-123-FP-CIT and F-18-FDG uptake values, respectively, using Pearson correlations and regression analyses. In addition, 2 masked interpreters evaluated the images visually, in both the routine and the experimental datasets, for comparison of patient diagnoses. Results: Parametric C-11-PE2I BPND and R-1 images showed high consistency with I-123-FP-CIT SPECT and F-18-FDG PET images. Correlations between C-11-PE2I BPND and I-123-FP-CIT uptake ratios were 0.97 and 0.76 in the putamen and caudate nucleus, respectively. Regional C-11-PE2I R-1 values were moderately to highly correlated with normalized F-18-FDG values (range, 0.61-0.94). Visual assessment of DAT availability showed a high consistency between C-11-PE2I BPND and I-123-FP-CIT images, whereas the consistency was somewhat lower for appraisal of overall brain functional activity using I-123-FP-CIT and F-18-FDG images. Substantial differences were found between clinical diagnosis and both neuro-imaging diagnoses. Conclusion: A single, dynamic C-11-PE2I PET investigation is a powerful alternative to a dual examination with I-123-FP-CIT SPECT and F-18-FDG PET for differential diagnosis of parkinsonian disorders. A large-scale patient study is, however, needed to further investigate distinct pathologic patterns in overall brain functional activity for various parkinsonian disorders.
引用
收藏
页码:234 / 242
页数:9
相关论文
共 40 条
  • [1] Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia
    Boeve, BF
    Lang, AE
    Litvan, I
    [J]. ANNALS OF NEUROLOGY, 2003, 54 : S15 - S19
  • [2] SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease
    Booij, Jan
    Knol, Remco J. J.
    [J]. PARKINSONISM & RELATED DISORDERS, 2007, 13 : S425 - S428
  • [3] Booij J, 2007, J NUCL MED, V48, P359
  • [4] Imaging Approaches to Parkinson Disease
    Brooks, David J.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (04) : 596 - 609
  • [5] Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes
    Catafau, AM
    Tolosa, E
    [J]. MOVEMENT DISORDERS, 2004, 19 (10) : 1175 - 1182
  • [6] Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy
    Ciumas, C.
    Wahlin, T. -B. Robins
    Jucaite, A.
    Lindstrom, P.
    Halldin, C.
    Savic, I.
    [J]. NEUROLOGY, 2008, 71 (11) : 788 - 794
  • [7] The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration
    Cummings, Jeffrey L.
    Henchcliffe, Claire
    Schaier, Sharon
    Simuni, Tanya
    Waxman, Alan
    Kemp, Paul
    [J]. BRAIN, 2011, 134 : 3146 - 3166
  • [8] EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2
    Darcourt, Jacques
    Booij, Jan
    Tatsch, Klaus
    Varrone, Andrea
    Borght, Thierry Vander
    Kapucu, Oezlem L.
    Nagren, Kjell
    Nobili, Flavio
    Walker, Zuzana
    Van Laere, Koen
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (02) : 443 - 450
  • [9] SEP-225289 Serotonin and Dopamine Transporter Occupancy: A PET Study
    DeLorenzo, Christine
    Lichenstein, Sarah
    Schaefer, Karen
    Dunn, Judith
    Marshall, Randall
    Organisak, Lisa
    Kharidia, Jahnavi
    Robertson, Brigitte
    Mann, J. John
    Parsey, Ramin V.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (07) : 1150 - 1155
  • [10] Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography
    DeLorenzo, Christine
    Kumar, J. S. Dileep
    Zanderigo, Francesca
    Mann, J. John
    Parsey, Ramin V.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2009, 29 (07) : 1332 - 1345